Niclosamide nanoemulsion for colorectal cancer: development, physicochemical characterization, and in vitro anticancer activity
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Curcumin's Biomedical Applications · Computational Drug Discovery Methods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 14:10117410.1016/j.tranon.2021.101174 ↗
2. Johnston L, Carey F (2020) Pathology of colorectal polyps and cancer. Surg Infect (Larchmt) 38:12–17
3. Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE (2021) Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. Int J Mol Sci 22:13010.3390/ijms22010130 ↗
4. Xie YH, Chen YX, Fang JY (2020) Comprehensive review of targeted therapy for colorectal cancer. Nat Signal Transduct Target Therapy 5:2210.1038/s41392-020-0116-z ↗
5. Hua Y, Dai X, Xu Y, Xing G, Liu H, Lu T, Chen Y, Zhang Y (2022) Drug repositioning: progress and challenges in drug discovery for various diseases. Eur J Med Chem 234:11423910.1016/j.ejmech.2022.114239 ↗
6. Kumar R, Coronel L, Somalanka B, Raju A, Aning OA, An O, Ho YS, Chen S, Mak SY, Hor PY, Yang H, Lakshmanan M, Itoh H, Tan SY, Lim YK, Wong APC, Chew SH, Huynh TH, Goh BC, Lim CY, Tergaonkar V, Cheok CF (2018) Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun 9:393110.1038/s41467-018-05805-1 ↗
7. Chen W, Mook RA Jr, Premont RT, Wang J (2018) Niclosamide: beyond an antihelminthic drug. Cell Signal 41:89–9610.1016/j.cellsig.2017.04.001 ↗
8. Kasim NA, Whitehouse M, Ramachandran C, Bemejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85–9610.1021/mp034006h ↗
9. Bhanushali JS, Dhiman S, Nandi U, Bharate SS (2022) Molecular interactions of niclosamide with hydroxyethyl cellulose in binary and ternary amorphous solid dispersions for synergistic enhancement of water solubility and oral pharmacokinetics in rats. Int J Pharm 626:12214410.1016/j.ijpharm.2022.122144 ↗
10. Jara MO, Warnken ZN, Willians RO III (2021) Amorphous solid dispersions and the contribution of nanoparticles to in vitro dissolution and in vivo testing: niclosamide as a case study. Pharmaceutics 13:9710.3390/pharmaceutics13010097 ↗
11. Costabile G, d’ Angelo I, Rampioni G, Bondi R, Pompili B, Ascenzioni F, Mitidieri E, Bianca REV, Sorrentino R, Miro A, Quaglia F, Imperi F, Leoni L, Ungaro F (2015) Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: development of Inhalable formulations through nanosuspension technology. Mol Pharmaceuctis 12:2604–261710.1021/acs.molpharmaceut.5b00098 ↗
12. Syamprasad NP, Madje N, Bachannagari J, Jannu AK, Jain S, Tene K, Pa S, Naidu VGM, Chella N (2023) Niclosamide nanocrystal for enhanced in-vivo efficacy against gastrointestinal stromal tumor via regulating EGFR/STAT-3/DR-4 axis. J Drug Deliv Sci Technol 81:10422110.1016/j.jddst.2023.104221 ↗
13. Zeyada MS, Abdel-Rahman N, El-Karef A, Yahia S, El-Sherbiny I, Eissa LA (2020) Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways. Life Sci 261:11845810.1016/j.lfs.2020.118458 ↗
14. Mansour A, Mahmoud MY, Bakr AF, Ghoniem MG, Adam FA, El-Sherbiny IM (2023) Fortified anti-proliferative activity of niclosamide for breast cancer treatment: In-vitro and in-vivo assessment. Life Sci 316:12137910.1016/j.lfs.2023.121379 ↗
15. Sanphui P, Kumar S, Nangia A (2012) Pharmaceutical cocrystals of niclosamide. Cryst Growth Des 12:4588–459910.1021/cg300784v ↗
16. Grifasi F, Chierotti MR, Gaglioti K, Gobetto R, Maini L, Braga D, Dichiarante E, Curzi M (2015) Using salt cocrystals to improve the solubility of niclosamide. Cryst Growth Des 15:1939–194810.1021/acs.cgd.5b00106 ↗
17. Lodagekar A, Borkar RM, Thatikonda S, Chavan RB, Naidu VGM, Shastri NR, Srinivas R, Chella N (2019) Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide. Carbohyd Polym 212:252–25910.1016/j.carbpol.2019.02.041 ↗
18. Liu L, Chen Y, Chen L, Shi Y, Fang J, Zhao M, Wang M (2023) Preparation and pharmacodynamics of niclosamide-hydroxypropyl-ß-cyclodextrin inclusion complex. J Drug Deliv Sci Technol 79:10403110.1016/j.jddst.2022.104031 ↗
19. Reyes Y, Hamzehlou S, Leiza JR (2021) Ostwald ripening in nano/miniemulsions in the presence of two costabilizers as revealed by molecular dynamics simulation. J Mol Liq 335:11615210.1016/j.molliq.2021.116152 ↗
20. de Souza A, Yukuyama MN, Barbosa EJ, Monteiro LM, Faloppa ACB, Calixto LA, de Araujo GLB, Fotaki N, Löbenberg R, Bou-Chacra NA (2020) A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids Surf B: Interfaces 193:11109710.1016/j.colsurfb.2020.111097 ↗
21. Russo A, Pellosi DS, Pagliara V, Milone MR, Pucci B, Caetano W, Hioka N, Budillon A, Ungaro F, Russo G, Quaglia F (2016) Biotin-targeted Pluronic1 P123/F127 mixed micelles delivering niclosamide: a repositioning strategy to treat drug-resistant lung cancer cells. Int J Pharm 511:127–13910.1016/j.ijpharm.2016.06.118 ↗
22. Kawish SM, Hasan N, Beg S, Qadir A, Jain GK, Aqil M, Ahmad FJ (2022) Docetaxel-loaded borage seed oil nanoemulsion with improved antitumor activity for solid tumor treatment: formulation development, in vitro, in silico and in vivo evaluation. J Drug Deliv Sci Technol 75:10369310.1016/j.jddst.2022.103693 ↗
23. Moya-Andérico L, Vukomanovi M, Cendra MM, Segura-Feliu M, Gil V, del Río J, Torrents E (2021) Utility of Galleria mellonella larvae for evaluating nanoparticle toxicology. Chemosphere 266:12923510.1016/j.chemosphere.2020.129235 ↗
24. Metzger W, Sossong D, Bächle A, Pütz N, Wennemuth G, Pohlemann T, Oberringer M (2011) The liquid overlay technique is the key to formation of co-culture spheroiods consisting of primary osteoblasts, fibroblasts and endothelial cells. Cytotherapy 13:1000–101210.3109/14653249.2011.583233 ↗
25. van Tonder EC, Maleka TSP, Liebenberg W, Song M, Wurster DE, de Villiers MM (2004) Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm 269:417–43210.1016/j.ijpharm.2003.09.035 ↗
26. Villiers MM, Pharm B, Mahlatji MD, van Tonder EC, Malan SF, Lötter AP, Liebenberg W (2004) Comparison of the physical and chemical stability of niclosamide crystal forms in aqueous versus nonaqueous suspensions. Drug Dev Ind Pharm 30:581–59210.1081/DDC-120037489 ↗
27. Alhalaweh A, Alzghoul A, Kaialy W, Mahlin D, Bergström CAS (2014) Computational predictions of glass-forming ability and crystallization tendency of drug molecules. Mol Pharm 11:3123–313210.1021/mp500303a ↗
28. Alskär LC, Keemink J, Johannesson J, Porter CJH, Bergström CAS (2018) Impact of drug physicochemical properties on lipolysis-triggered drug supersaturation and precipitation from lipid-based formulations. Mol Pharm 15:4733–474410.1021/acs.molpharmaceut.8b00699 ↗
29. Jara MO, Williams RO III (2023) The challenge of repurposing niclosamide: considering pharmacokinetic parameters, routes of administration, and drug metabolism. J Drug Deliv Sci Technol 81:10418710.1016/j.jddst.2023.104187 ↗
30. Göke K, Bunjes H (2017) Drug solubility in lipid nanocarriers: Influence of lipid matrix and available interfacial area. Int J Pharm 529:617–62810.1016/j.ijpharm.2017.07.025 ↗
31. Gautshi N, Bergström CAS, Kuentz M (2016) Rapid determination of drug solubilization versus supersaturation in natural and digested lipids. Int J Pharm 513:164–17410.1016/j.ijpharm.2016.09.015 ↗
32. Cao Y, Marra M, Anderson BD (2004) Predictive relationships for the effects of triglyceride ester concentration and water uptake on solubility and partitioning of small molecules into lipid vehicles. J Pharmaceut Sci 93:1110.1002/jps.20126 ↗
33. Zhang C, Zhang L, Xu T, Xue R, Yu L, Zhu Y, Wu Y, Zhang Q, Li D, Shen S, Tan D, Bai F, Zhang H (2020) Mapping the spreading routes of lymphatic metastases in human colorectal cancer. Nat Commun 11:199310.1038/s41467-020-15886-6 ↗
34. Broks DR, Davies NM (2018) Lymphatic drug absorption via the enterocytes: pharmacokinetics simulation, modeling, and considerations for optimal drug development. J Pharm Pharm Sci 21:254–27010.18433/jpps30217 ↗
35. Zhang Z, Lu Y, Qi J, Wu W (2021) An update on oral drug delivery via intestinal lymphatic transport. Acta Pharmaceutica Sinica B 11:2449–246810.1016/j.apsb.2020.12.022 ↗
36. Caliph SM, Charman WN, Porter CJH (2000) Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 89:1073–108410.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V ↗
37. Imada C, Takahashi T, Kuramoto M, Masuda K, Ogawara K, Sato A, Wataya Y, Kim HS, Higaki K (2015) Improvement of oral bioavailability of N-251, a novel antimalarial drug, by increasing lymphatic transport with long-chain fatty acid-based self-nanoemulsifying drug delivery system. Pharm Res 32:2595–2608
38. Mu H, Høy CR (2000) Effects of different medium-chain fatty acids on intestinal absorption of structured triglycerols. Lipids 35:83–8910.1007/s11745-000-0498-x ↗
39. Watkins PA (2018) The fatty acyl-CoA synthetases. Reference Module in Biomedical Sciences. Elsevier
40. Cifarelli V, Abumrad NA (2018) Chapter 48: Enterocyte fatty acid handling proteins and chylomicron formation. In: Physiology of the gastrointestinal tract. Academic Press, 6ed 1087–110710.1016/B978-0-12-809954-4.00048-7 ↗
41. Xia D, Hu C, Hou Y (2023) Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption. Eur J Pharm Biopharm 185:165–17610.1016/j.ejpb.2023.02.016 ↗
42. Francke NM, Schneider F, Baumann K, Bunjes H (2021) Formulation of cannabidiol in colloidal lipid carriers. Molecules 26:1469–148710.3390/molecules26051469 ↗
43. Real DA, Hoffmann S, Leonardi D, Goycoolea FM, Salomon CJ (2021) A quality by design approach for optimization of Lecithin/Span® 80 based nanoemulsions loaded with hydrophobic drugs. J Mol Liq 321:11474310.1016/j.molliq.2020.114743 ↗
44. Cole L, Fernandes D, Hussain MT, Kaszuba M, Stenson J, Markova N (2021) Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for gene therapy using orthogonal techniques. Pharmaceutics 13:58610.3390/pharmaceutics13040586 ↗
45. Zarrintaj P, Ramsey JD, Samadi A, Atoufi Z, Yazdi MK, Ganjali MR, Amirabad LM, Zangene E, Farokhi M, Formela K, Saeb MR, Mozafari M, Thomas S (2020) Poloxamer: a versatile tri-block copolymer for biomedical applications. Acta Biomater 110:37–6710.1016/j.actbio.2020.04.028 ↗
46. Halder J, Pradhan D, Kar B, Ghosh G, Rath G (2022) Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomed: Nanotechnol, Biol Med 40:10249410.1016/j.nano.2021.102494 ↗
47. Hamdoun S, Jung P, Efferth T (2017) Drug repurposing of the anthelmintic niclosamide to treat multidrug-resistant leukemia. Front Pharmacol 8:11010.3389/fphar.2017.00110 ↗
48. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA, Lyerly HK (2011) Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res– Therapeut Targets, Chem Biol 71:4172–4182
49. Monin MB, Krause P, Stelling R, Bocuk D, Niebert S, Klemm F, Pukrop T, Koenig S (2016) The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. J Surg Res 203:193–20510.1016/j.jss.2016.03.051 ↗
50. Tomeh MA, Hadianamrei R, Sun W, Xu D, Brown S, Zhao X (2021) Stiffness-tuneable nanocarriers for controlled delivery of ASC-j9 into colorectal cancer cells. J Colloid Interface Sci 594:513–52110.1016/j.jcis.2021.03.086 ↗
51. He X, Yang Y, Han Y, Cao C, Zhang Z, Li L, Xiao C, Guo H, Wang L, Han L, Qu Z, Liu N, Han S, Xu F (2023) Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment. PNAS 120:e220926012010.1073/pnas.2209260120 ↗
52. Tchoryk A, Taresco V, Argent RH, Ashford M, Gellert PR, Stolnik S, Grabowska A, Garnett MC (2019) Penetration and Uptake of Nanoparticles in 3D Tumor Spheroids. Bioconjug Chem 30:1371–138410.1021/acs.bioconjchem.9b00136 ↗